trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['gastric', 'trastuzumab deruxtecan', 'rux,(-crux),(-trux)', 'lung', 'breast']
 trastuzumab deruxtecan is a potent antibody-drug conjugate that has become a standard of care for her2-low as well as her2-positive breast cancer, her2-positive gastric cancer, and her2-mutant lung cancer, said funda meric-bernstam, md. #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.